Dr. Dolores Shoback cares for patients with a variety of disorders related to the endocrine system, focusing particularly on metabolic bone disease, parathyroid disorders and osteoporosis. She also directs UCSF's physician training program in diabetes, endocrinology and metabolism.

Shoback's research interests include metabolic bone disease, the calcium-sensing receptor and parathyroid hormone.

Shoback completed her undergraduate studies at the University of Pennsylvania. She earned her medical degree from the Johns Hopkins School of Medicine and completed a residency in internal medicine at the Johns Hopkins Hospital. She completed a fellowship in endocrinology at Brigham and Women's Hospital.

  • Education

    Johns Hopkins School of Medicine, 1977

  • Residencies

    Johns Hopkins Hospital, Internal Medicine, 1980

  • Fellowships

    Brigham and Women's Hospital, Endocrinology, 1983

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

  • Academic Title


Clinics I work with

Endocrinology Clinic at Parnassus

400 Parnassus Ave., Suite A-550
San Francisco, CA 94143

Metabolic Bone Clinic

400 Parnassus Ave., Fifth Floor, Suite A-550
San Francisco, CA 94143

My reviews


Overall Experience
70 Reviews
Dr. Shoback carefully explained possible causes of my medical condition in ways I understood. I am so happy to have her leading my care - I have complete confidence in her treatment plan. I also appreciated that she was friendly professional and clearly respected my input. Thank you Dr. Shoback.
Explained things in a way that was easy to understand
70 Reviews
Did the doctor pay attention to your concerns
70 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
69 Reviews
Knew the important information about your medical history
70 Reviews
The provider showed respect for what you had to say
69 Reviews
The provider spent enough time with me
70 Reviews
Decorative Caduceus

Novel Combination Therapy for Osteoporosis in Men

Hypothesis 1a proposes that BMD responses to combined TPTD+cinacalcet are greater than those induced by TPTD+PBO. LS BMD typically responds quickly and robustly to TPTD and is the 1o endpoint of the trial. DXA measurements will be...